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Abstract
Background: Japanese encephalitis (JE) is presumed to be endemic throughout Asia, yet only a
few cases have been reported in tropical Asian countries such as Indonesia, Malaysia and the
Philippines. To estimate the true disease burden due to JE in this region, we conducted a
prospective, hospital-based surveillance with a catchment population of 599,120 children less than
12 years of age in Bali, Indonesia, from July 2001 through December 2003.
Methods: Balinese children presenting to any health care facility with acute viral encephalitis or
aseptic meningitis were enrolled. A "confirmed" diagnosis of JE required the detection of JE virus
(JEV)-specific IgM in cerebrospinal fluid, whereas a diagnosis of "probable JE" was assigned to those
cases in which JEV-specific IgM was detected only in serum.
Results: In all, 86 confirmed and 4 probable JE cases were identified. The annualized JE incidence
rate was 7.1 and adjusted to 8.2 per 100,000 for children less than 10 years of age over the 2.5
consecutive years of study. Only one JE case was found among 96,920 children 10–11 years old (0.4
per 100,000). Nine children (10%) died and 33 (37%) of the survivors had neurological sequelae at
discharge. JEV was transmitted in Bali year-round with 70% of cases in the rainy season.
Conclusion: JE incidence and case-fatality rates in Bali were comparable to those of other JE-
endemic countries of Asia. Our findings contradict the common wisdom that JE is rare in tropical
Asia. Hence, the geographical range of endemic JE is broader than previously described. The results
of the study support the need to introduce JE vaccination into Bali.
Background
Japanese encephalitis (JE), a mosquito-borne viral infec-
tion, has a high case-fatality rate (10%–30%) [1,2] with
30%–50% of survivors left with long-term neurological
disability [3,4]. Some 35,000 to 50,000 cases of JE are
reported annually [1-4], a likely underestimate given that
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lowing the successful control of poliomyelitis, JE has
become a major cause of neurological disability among
Asian children.
Culex tritaeniorhynchus, the major mosquito vector of JE
virus (JEV), breeds by laying eggs in wet rice fields [1]. JEV
is transmitted by mosquito vectors to a variety of mam-
mals and birds [1,5]. Pigs are the most efficient amplifying
hosts for dissemination of JEV, capable of exhibiting up to
9 logs of viremia [6,7]. Thus, rural areas with both rice
fields and pigpens provide the best habitats for propaga-
tion and transmission of JEV. Children remain the main
victims of the disease [2,8]. Most JE infections are asymp-
tomatic, and the ratio of symptomatic to asymptomatic
infections ranges from 1 in 300 to 1 in 1,000 [9-12].
JE incidence declined dramatically in Japan, Korea, China
and Thailand after JE vaccine was mandated in routine
childhood immunization programs [13]. Most other
Asian countries have not implemented JE vaccination pro-
grams, owing partly to inadequate documentation of JE
risk. For example, in Indonesia, Malaysia and the Philip-
pines, only 284 JE cases were reported between 1986 and
1996, compared with thousands of cases during the same
period in the neighboring countries of Thailand and Viet-
nam, which share similar natural ecological conditions
[14]. We believed the low JE incidence in Malaysia, Indo-
nesia and the Philippines probably reflected an underesti-
mate due to lack of JE surveillance activities and
diagnostic capabilities. To determine the potential high
risk of JE in this region, we conducted a prospective hos-




Bali, an island located 8–9 degrees south of the equator,
has mean monthly temperatures of 20–35°C and a rainy
season that extends from November through April. Of
approximately 3 million residents, 90% are Hindu farm-
ers. They raise pigs and grow rice year-round, providing
persistent breeding sites for JE mosquito vectors. Health
care is affordable and accessible by most families. The
island is divided into nine administrative units (8 districts
and 1 town), each equipped with a government-spon-
sored modern hospital, several sub-district health centers
and many village health clinics. In addition, 14 private
clinics provide pediatric outpatient care; inpatient serv-
ices, however, are provided by 10 government hospitals (1
military).
JE surveillance system
In July 2001, we established a case referral system that
included all health care facilities on the island providing
care for children under 12 years of age (599,120 children).
The pediatric inpatient departments of the 10 govern-
ment-sponsored provincial and district hospitals were
used as surveillance centers. Patients suspected of JE were
referred from other health care facilities to 1 of the 10 sur-
veillance centers for further evaluation and treatment. All
pediatricians who work on infectious diseases from the 10
surveillance centers and a subset of general practitioners
from sub-district health centers attended workshops
designed to increase awareness of JE and to define the safe
handling of patients and specimens; they were also
encouraged to report and refer suspected JE cases. Televi-
sion programs and newspapers encouraged parents to
bring children with signs or symptoms suggestive of JE to
surveillance centers for treatment.
Enrollment criteria
Children suspected of JE were eligible for this study if they
were Bali residents under 12 years of age, and were admit-
ted or referred to one of the pediatric departments of the
ten surveillance centers. A suspected case was defined as a
child who experienced acute onset of fever (body temper-
ature = 38°C, axillary) with any neurological deficits (e.g.,
seizure, cranial nerve or sensory deficits, abnormal move-
ments, weakness of one or more limbs) and/or changes in
mental status (e.g., confusion, disorientation or coma)
and/or signs of meningeal irritation (e.g., headache, vom-
iting, neck stiffness, Kernig's Sign). Exclusion criteria
included confirmed bacterial meningitis, cerebral malaria
and tumors causing similar neurological deficits.
Clinical evaluations and specimen collection
The institutional review boards of the Udayana University
in Bali, the International Vaccine Institute (IVI) in Seoul,
and the Program for Appropriate Technology for Health
(PATH) in Seattle reviewed and approved the study docu-
ments. Written informed consent was obtained from par-
ents or guardians prior to enrollment of their children in
the study. Clinical symptoms on admission and upon dis-
charge were captured on case report forms. Venous blood
and cerebrospinal fluid (CSF) were collected on admis-
sion and whenever possible upon follow-up, usually 1–2
weeks later. Initial laboratory evaluations aimed to rule
out treatable meningitis with a bacterial etiology. Speci-
mens were stored at -70°C for further tests.
Confirmatory diagnosis of JE
The laboratory protocol of JE diagnosis was based on
detection of anti-JEV IgM in CSF or serum by the enzyme-
linked immunosorbent assay (MAC ELISA) as described
by Burke and colleagues [15,16]; test reagents were pro-
vided by the Armed Forces Research Institute of Medical
Sciences (AFRIMS) in Bangkok. A subject was diagnosed
with "confirmed JE" if anti-JEV IgM was present in the CSF
(1:10 dilution). If the virus-specific IgM was detected onlyPage 2 of 7
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was considered. Because dengue virus, another flavivirus,
co-circulates with JEV within the study area, an IgM cap-
ture ELISA for dengue was concurrently performed on all
specimens [17].
Statistical methods
The population was projected for 2001–2003 on the basis
of a 2000 census. We used a Poisson model to estimate the
effects of age intervals on incidence rates [18]. Data clean-
ing and verification programs and final data analyses were
completed using the STATA/SE 8 and Microsoft Access
(version 2002) software programs.
Results
Enrollment and verification of JE patients
From July 2001 through December 2003, 239 eligible
children were enrolled. Of these, 140 (59%) directly vis-
ited one of the ten surveillance centers, 27 (11%) and 43
(18%) were referred from sub-district health centers and
village health clinics, respectively, and 29 (12%) were
referred from private clinics.
Admission CSF and serum specimens were obtained from
all enrolled children, but convalescent CSF samples were
only available for 104 patients. Of the 239 enrollees, 86
(36%) were classified as "confirmed JE" (CSF detection),
4 (2%) as "probable JE" (only serum detection) and 149
(62%) as "non-JE encephalitis." No anti-dengue IgM anti-
bodies were detected in CSF or serum specimens.
JE incidence and case-fatality rates
Among the 86 confirmed and 4 probable JE patients, only
1 was over 10 years. Considering the timing of the remain-
ing 89 JE cases, the attack rate for the first 6 months of sur-
veillance (July to December 2001) was similar to the
subsequent two calendar years, with an average annual
detection of 36 cases. Thus, the annualized JE incidence
per 100,000 children less than 10 years of age in Bali was
7.1 in 2001, 7.0 in 2002, and 7.1 in 2003, respectively,
with an average of 7.1 (95% confidence interval [CI], 3.6–
10.5 per 100,000). Seventy percent of the cases were
younger than 5 years, giving an annualized JE incidence of
9.1 per 100,000 (95% CI, 5.6–12.7). The rates were 4.6
(95% CI, 1.8–7.4) and 0.4 (95% CI, 0–1.7) for the age
groups of 5–9 and 10–11 years, respectively (Table 1). The
male-to-female ratio was 1.7:1 (P < 0.05); however, the
ratio was 1:1.2 among cases <12 months old.
Potential impact of incomplete availability of second CSF 
specimen
A past study suggests that anti-JEV IgM levels in CSF usu-
ally peak during the 2nd to 4th week of illness, and only
75% of confirmed JE cases have detectable IgM antibodies
in CSF specimens during the first week of illness [19]. In
our study, of the 135 patients with admission-only CSF
samples collected during the first week of illness, 32
(24%) exhibited positive anti-JEV IgM. Of the 104 enroll-
ees with convalescence CSF samples collected at least 1
week after illness onset, 54 (52%) tested positive for anti-
JEV IgM. The positivity rate for the paired CSF group was
significantly higher than for the acute phase-only CSF
Table 1: Age-sex distribution of Japanese encephalitis cases among Balinese children, July 2001 and December 2003





0 – 4 38 (2) 22 (1) 60 (3) 275,500 9.1 (5.6–12.7)
5 – 9 15 (1) 10 (0) 25 (1) 226,700 4.6 (1.8–7.4)
10 – 11 1 (0) 0 (0) 1 (0) 96,920 0.4 (0–1.7)
Total 0–11 54 (3) 32 (1) 86 (4) 599,120 6.0 (4.1–8.0)
† per 100,000
Table 2: Discharge status of Japanese encephalitis cases in surveillance hospitals, Bali, July 2001 and December 2003
Discharge status Confirmed JE (n = 86) Probable JE (n = 4) Total (n = 90)
Alive and well 43 (50%) 2 (50%) 45 (50%)
Alive but disabled 31 (36%) 2 (50%) 33 (37%)
Alive but still sick 3 (3%) 0 (0%) 3 (3%)
Dead 9 (11%) 0 (0%) 9 (10%)
Total 86 (100%) 4 (100%) 90 (100%)Page 3 of 7
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cases with paired CSF samples, 38 (70%) demonstrated
anti-JEV IgM in both specimens. The remaining 16 (30%)
cases had negative first samples but positive convales-
cence samples. Therefore, in addition to the 32 (70%)
confirmed JE cases in the acute phase-only CSF group, 14
(30%) more JE cases would have been detected if two
sequential CSF samples had been collected for this group.
Discharge status of children infected with JE
Nine (11%) of the 86 children with confirmed JE died
during hospitalization. Of the survivors, 31 (36%) had
symptomatic neurological sequelae at discharge that
included muscular paralysis, increased tonus, ataxia, epi-
lepsy, clonus, chorea and respiratory distress. Of the 4
probable JE cases, 2 were fully recovered, 1 had aphasia
and limb paralysis, and 1 had aphasia and extra-pyrami-
dal symptoms (Table 2).
Distribution of JE cases by month
As shown in Figure 1, no calendar month consistently
lacked reports of JE cases throughout the 2.5-year study
period, though several calendar months showed at least
one JE case in one year but not in the other. For instance,
JE cases were reported during February and March in
2002, but not in 2003; no case was reported in September
and October of 2001, but 4 and 8 cases were reported in
these 2 calendar months in 2002 and 2003 respectively.
Hence, unlike the strict summer seasonality in temperate
JE-endemic countries [1,2], JEV appears to be transmitted
year-round in Bali. Seventy percent of JE cases were
detected between December and May, a typical 1-month
lag behind the usual rainy season (November-April),
which is required for JEV incubation and dissemination.
Geographical distribution of JE
JE occurred in all nine administrative districts of Bali. The
incidence was higher in the southern plains, where rice
fields are more widely distributed, than in the mountain-
ous districts of northern Bali.
Only one village produced more than a single JE case dur-
ing the course of the study. The interval between the onset
of illness for the 2 cases was 2.5 months, five times longer
than the average 2-week incubation period of the disease,
suggesting that these cases were unrelated.
Discussion
Tropical countries of eastern Asia (Indonesia, Malaysia
and the Philippines) have conventionally been consid-
ered to have low JE risk [2]. In Indonesia, for example,
only 41 JE cases were reported for the whole country dur-
ing the 11 years from 1986 through 1996 [14]. Although
JEV was isolated from the mosquito vector in 1972 and
serological surveys confirmed the prevalence of JEV infec-
tions in endemic wild birds and domestic animals, only
sporadic human JE cases have been reported in Indonesia
[20-22]. Previously, this low JE-risk to humans was attrib-
uted to a less virulent JEV circulating in the region [23].
Our study results suggest the contrary. In Bali alone we
identified 90 JE cases in humans within just 2.5 years.
Even this may be an underestimate given that 135 of the
239 suspected JE cases provided only acute-phase CSF
samples within the 1st week of illness onset, of which only
32 JE cases were detected. If we assume that 30% of JE
cases were undiagnosed in the acute-phase-only CSF
group, approximately 14 additional JE cases would have
been detected if a convalescence CSF sample had been
available, making the total confirmed and probable JE
cases 104. The annualized JE incidence rate among chil-
dren under 10 years of age could then be adjusted from
7.1 to 8.2 per 100,000. Thus, the data obtained through
comprehensive surveillance indicate that JEV is hyperen-
demic in Bali, that it causes substantial human illness, and
that it circulates year-round. Our findings in a tropical
country that was presumed to have low risk of JE may
necessitate more intensive surveillance to assess JE-risk
fully in other countries of tropical Asia.
Most evaluations of JE disease burden have been based on
clinical reports of acute viral encephalitis without labora-
tory confirmation. Accurate estimation of age-specific
incidence of JE is rare. The pre-adjusted annual incidence
rates of 9.1 per 100,000 in children 0–4 years of age and
7.1 per 100,000 in children 0–9 years in Bali are similar to
the incidence rates of 7–11 per 100,000 among children
aged 0–9 years living in high-risk provinces of northern
Average monthly hospital admission of children with Japa-nese encephalitis (JE) in Bali, Indonesia, July 2001 through Decemb r 2003Figure 1
Average monthly hospital admission of children with Japa-
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in endemic areas of Taiwan [3,24,25]. Age-specific inci-
dence rates in placebo groups observed during vaccine tri-
als in Asian countries have fluctuated between 15 and 25
per 100,000 [14]. However, the study populations for vac-
cine trials are selected from high-risk areas, and JE inci-
dence in such studies is measured more rigorously using
advanced technologies.
JE in temperate and subtropical Asian countries (China,
Japan, Korea, Nepal, northern Vietnam and northern
Thailand) is characterized by cyclic epidemics and JE out-
breaks every 5–15 years [26]. During the inter-epidemic
years, JE incidence rates significantly decline [2,4]. In con-
trast, in Bali, we observed consistent JE incidence rates of
about 7.1 per 100,000 over 2.5 consecutive years. Further
studies are needed to assess the validity of this finding
over longer periods of time and to determine whether
cyclic epidemics occur in Bali. In temperate JE-epidemic
regions, a strict summer seasonality of JE has been
observed; the mechanism of over-wintering of the virus in
the winter and spring is unclear [1,4,5]. In Bali, where JEV
appears to circulate year-round, this mechanism may not
apply.
In the northern regions of Thailand and Vietnam, the
highest JE attack rates are in children aged 5–9 years [27-
29]. In Bali, however, 70% of the JE cases were children
under 5 years of age (Table 1). This suggests a greater
intensity of transmission that exposes children to JEV at a
younger age. Similar to findings elsewhere, our study sug-
gests that amongst children above the age of 1 year, males
have a greater predilection to JE than females. This may be
related to boys engaging in more outdoor activities than
girls, leading to greater exposure to JE-infected mosqui-
toes [3,4]. Also consistent with other studies, no clustering
of JE cases was evident [3,4]. Though emergency yellow
fever immunization in response to yellow fever outbreaks
is effective in ameliorating the person-to-person transmis-
sion involving domicile mosquitoes [30], such a strategy
of emergent JE vaccination in response to identification of
an initial JE case would be ineffective.
The transmission cycle of JEV relies solely on the mos-
quito vector and the amplifying non-human host (prima-
rily the pig). Humans are accidental hosts and are not
required for virus transmission. Bali represents an interest-
ing, but not necessarily unique, ecological setting wherein
both pig raising and rice farming take place year-round,
representing ideal conditions for consistent JEV propaga-
tion. As Balinese are predominantly Hindu (unlike other
Indonesians, who are predominantly Muslim), pork is a
major food item with a pig-to-human population ratio of
approximately 1:2. We found that 280 (70%) of 400 pigs
in Bali showed hemagglutination inhibition antibody
against JEV (unpublished data). Consequently, pigs prob-
ably serve as the primary amplifying hosts of JEV in Bali.
Rice cultivation in Bali is not seasonal. Therefore, only
parts of rice fields are filled with water at any given time
and they are periodically drained as part of intermittent
irrigation practice [31]. As a result, the rainy season
appears to facilitate water filling and mosquito breeding
within the rice fields. Hence, the tropical climate and agri-
cultural practices in Bali work in concert to accelerate the
year-round transmission of JEV via the animal-mosquito
cycle.
We note certain study limitations. First, JE infections were
found in children presenting with acute flaccid paralysis
(AFP) in southern Vietnam [32]. In retrospect, we found
that we failed to include 14 AFP cases documented within
Bali whose ages were within the case definition of our sur-
veillance. Second, our surveillance approach targeted chil-
dren seeking medical attention and missed JE cases that
may have led to early pre-hospital deaths. Likewise, mild
JE cases manifesting only by febrile convulsions may have
been missed. These omissions may have contributed fur-
ther to the underestimation of true JE incidence in our
study.
Conclusion
Given the particular social and ecological setting, the data
obtained from Bali may or may not be applicable to the
rest of Indonesia. However, our findings clearly suggest
that countries previously classified as at low JE risk may be
so only because of insufficient surveillance data. Addi-
tional studies are warranted in areas presumed to have
low JE risk.
Current JE vaccines are safe, effective and cost-effective
[33-35]. By any standard, JE is a major public health prob-
lem in Bali and will remain so given that humans are acci-
dental (not required) hosts in the vector-animal (pig)
transmission cycle. Effective JE vaccination programs pro-
vide the only solution to the ongoing threat of JE to
endemic populations such as those on Bali.
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